Mrinalini Dey

Delighted to share our paper on #multimorbidity in #RA emphasising a need for: -Operationalised definition of MM -Clearer distinction between MM & #comorbidity in literature -Greater understanding of MM to encourage holistic care @RheumJnl @ElenaNikiUK academic.oup.com/rheumatology/a…

Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty. Register: buff.ly/ILFPuhf @RheumNow

Day 2 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap. buff.ly/i6Eo3G3

AI in Fellow Recruitment: A New Dawn in Medical Education? Drs. Mrinalini Dey and Bharat Kumar abstract 2174 (Using Natural Language Processing to Identify Character Strengths in Rheumatology Fellowship Candidate Applications: A Feasibility Study) presented at #ACR25. buff.ly/9jZM07e

Upadacitinib: revisiting safety data in RA and GCA For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, many of us continue to reach for upadacitinib when we face challenges in treatment, from rheumatoid arthritis to axial spondyloarthritis. buff.ly/5hgvKpZ

New content online: Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis bit.ly/495WzlJ

GLP-1 Receptor Agonists: Impacts Beyond Metabolism? Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients. #ACR25 buff.ly/TECBQSz

Plenty to talk about when it comes to #AI at #ACR25! Read my thoughts below in this article for @RheumNow

What a conference! Thanks to all those who stopped by! #ACR25

@MithuRheum @UNMC_Rheum @RheumOnePagers Thank you for these summaries, they are incredibly helpful!

🆕 Clinical Year in Review at #ACR25 By Dr. Bryant England @UNMC_Rheum 🔶 Review the most impactful studies in #Rheumatology from the past year! ❓ Any studies you would add to the list? #RheumX #RheumTwitter #ACR2025

#2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & microstructure, worsening with disease activity. TNFi, RTX & BARI improved MCP bone density, highlighting the impact of inflammation and treatment. @RheumNow #ACR25

#2662 Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi No sig differences in mortality, resp, hospitalisation or lung transplant across groups, suggesting other b/tsDMARDs may be as safe as RTX for RAILD @RheumNow #ACR25

#2661 In >5000 veterans with RA-ILD, 8 distinct FVC trajectories were identified. >1/2showed a progressive decline (≥0.7%/yr). These progressive patterns predicted higher mortality & respiratory hospitalisations, underscoring major disease heterogeneity. @RheumNow #ACR25

#2702 @ClevelandClinic Vascular ultrasound (VUS) for suspected GCA showed excellent specificity (100%) but low sensitivity (21%) compared with 6m confirmed diagnosis. Fair agreement with TAB (κ=0.64). Findings highlight need for standardised VUS protocols in US. @RheumNow #ACR25

#2660 In >8000 women, serum urate rose sharply during the menopausal transition, then plateaued after menopause. Hyperuricemia reached 4-5% post-menopause, up to 18% in obesity or low eGFR. Healthy body weight & kidney function pre-menopause may decrease HU later @RheumNow #ACR25

#2682 In a randomised trial of 320 RA patients, the recombinant zoster vaccine (RZV) was safe and did not trigger disease flares. But methotrexate use and older age significantly blunted antibody responses ➡️key factors to consider for vaccine strategies in RA. @RheumNow #ACR25

#2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, were assoc with lower risks of RA, lupus, vasculitis & other autoimmune rheumatic diseases vs DPP-4 inhibitors. Possible immune benefits of SGLT2i? @RheumNow #ACR25

#2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory disease risk, and were instead linked to lower mortality, heart failure, stroke and dementia. Excellent real-world safety signals. @RheumNow #ACR25

#2681 Tackling the “lipid paradox” in RA: inflammation-adjusted TC & LDL (using hsCRP correction) improved ASCVD risk prediction and flagged more high-risk patients than standard lipids. A smarter way to guide statin use in RA. @RheumNow #ACR25

In the epidemiology session on the final day of #ACR25, a large cohort study (>430k pts) showed that GLP-1 receptor agonists were linked to lower incidence of RA, gout & OA vs DPP-4 inhibitors. Adds to the growing case for GLP-1 benefits beyond glucose control. @RheumNow #2657

#YearInPreview Steroid burden remains a big problem for people with #GCA, but new treatments, with promising safety data, are on the horizon, especially with the latest on #Upadacitinib presented at #ACR25 @RheumNow